Valladolid: Curia Global Inc, a global research, development, and manufacturing organization, has completed a US$4 million investment to upgrade its two active pharmaceutical ingredient (API) aseptic suites in Valladolid, Spain. The investment is aligned with the latest European Union Good Manufacturing Practice (EU GMP) Annex 1 standards, reinforcing the company’s commitment to regulatory excellence and product quality.
According to BERNAMA News Agency, Annex 1 provides guidance on the design and control of facilities, systems, and procedures for sterile manufacturing, applying Quality Risk Management principles to prevent microbial, particulate, and endotoxin contamination. Philip Macnabb, Curia’s Chief Executive Officer, highlighted that the improvements reflect Curia’s focus on reliability, precision, and trust, as the company continues to invest ahead of industry trends.
Macnabb stated, “Quality and compliance are integral to how we operate. The new Annex 1 requirements align with our proactive approach to quality control, and our customers can be assured of our commitment to deliver high-quality sterile APIs at scale.”
The investment has resulted in significant enhancements to the Valladolid site’s infrastructure and technology, including the installation of new isolators and modernization of HVAC systems, pharmaceutical panels, automation, sterilization equipment, and utilities. The transition to a fully closed system was the key focus of the upgrade to strengthen process safety and product sterility while improving ergonomic conditions and operator safety. Additional automated controls were introduced in line with stricter data integrity policies outlined under 21 CFR Part 11.
The Valladolid project followed a global assessment of Curia’s manufacturing network to identify opportunities for improvement in line with Annex 1 standards, covering equipment, utilities, qualifications, and validations. With over two decades of experience in API aseptic processing, Curia noted that the investment positions the company to handle increasingly complex manufacturing projects while reinforcing its commitment to producing life-changing medicines with uncompromising quality and reliability.